Searched for:
(1 - 2 of 2)
van der Ploeg, C.P.B. (author), Blom, M. (author), Bredius, R.G.M. (author), van der Burg, M. (author), Schielen, P.C.J.I. (author), Verkerk, P.H. (author), van den Akker-van Marle, M.E. (author)
Severe combined immunodeficiency (SCID) is a condition that often results in severe infections and death at young age. Early detection shortly after birth, followed by treatment before infections occur, largely increases the chances of survival. As the incidence of SCID is low, assessing cost-effectiveness of adding screening for SCID to the...
article 2019
van der Ploeg, C.P.B. (author), van den Akker-van Marle, M.E. (author), Vernooij-van Langen, A.M.M. (author), Elvers, L.H. (author), Gille, J.J.P. (author), Verkerk, P.H. (author), Dankert-Roelse, J.E. (author), Loeber, J.G. (author), Triepels, R.H. (author), van der Pal, S.M. (author), Dompeling, E. (author), Pals, G. (author), Gulmans, V.A.M. (author), Oey-Spauwen, M.J.W. (author), Wijnands, Y.H.H.M. (author), Castricum, L.M. (author), Arets, H.G.M. (author), van der Ent, C.K. (author), Tiddens, H.A.W.M. (author), de Rijke, Y.B. (author), Yntema, J.B. (author)
BACKGROUND: Previous cost-effectiveness studies using data from the literature showed that newborn screening for cystic fibrosis (NBSCF) is a good economic option with positive health effects and longer survival. METHODS: We used primary data to compare cost-effectiveness of four screening strategies for NBSCF, i.e. immunoreactive trypsinogen...
article 2015